Money & MarketsAstraZeneca’s vaccine is poised to become the leader in most of the worldUpdated July 20, 2022
Money & MarketsPfizer’s Covid-19 vaccine is set to be one of the most lucrative drugs in the worldUpdated July 20, 2022
Money & MarketsCovid-19 could teach US hospitals some lessons, if they’re willing to listenUpdated July 20, 2022
Money & MarketsA government crisis is poised to make Italy’s Covid-19 trouble even worseUpdated July 20, 2022
Money & MarketsCan Biden’s inauguration ceremony really unite Americans? History suggests soUpdated July 20, 2022
Money & MarketsThe crises looming over Biden’s inauguration make it all the more importantUpdated July 20, 2022
Money & MarketsHow to make sense of Angela Merkel’s criticism of the Trump Twitter banUpdated July 20, 2022
Money & MarketsWhy Jeff Bezos, Warren Buffett, and Jamie Dimon gave up on their venture to disrupt US healthcareUpdated July 20, 2022
Tech & InnovationHas Covid-19 permanently altered the development timetable for other vaccines?Updated July 21, 2022
Money & MarketsTo overcome vaccine skepticism, follow the British Muslim medical professionals’ approachUpdated July 21, 2022
Money & MarketsShould the Trump administration really have bought more Pfizer vaccine doses?Updated July 21, 2022
Tech & InnovationThe only cure strong enough for big pharma’s bad reputation is a Covid-19 vaccineUpdated July 21, 2022
LifestyleIn Maradona, the world mourns a legend—but Naples mourns a part of itselfUpdated July 21, 2022
